Healthcare Services company Indegene announced Q3FY25 results Achieved revenue of Rs 7,204 million in Q3FY25 compared to Rs 6,734 million during Q3FY24, a growth of 4.9% QoQ. Achieved PAT of Rs 1,097 million compared to Rs 988 million during Q3FY24, a growth of 19.6% QoQ. PAT margin: 15.2% for Q3FY25. EBITDA: Rs 1,501 million compared to Rs 1,499 million during Q3FY24. EBITDA margin: 20.8% for Q3FY25. Manish Gupta, Chairman and CEO, Indegene, said: “We have consistently grown our revenue, maintaining stable and profitable growth, and our Q3FY25 numbers reflect this. We achieved revenue growth of 4.9% QoQ driven by continued traction with large pharma customers and growth momentum with mid-size pharma customers. Our largest customer is continuing to grow, and we are doing a run-rate of a tad below USD 50 million with this customer” “We are seeing a steady increase in the revenues from our Top 5 customers, which have grown 3.1% sequentially in this period.” Suhas Prabhu, CFO, Indegene, said: ““Q3FY25 was another successful quarter for Indegene. We improved our EBITDA margin from 18.4% in Q2FY25 to 20.8% in Q3FY25. This was achieved via ongoing productivity improvement through better capacity management and automation, which helped absorb the impact of the annual employee wage hike effective July, fully and beyond” “Our earnings growth continues with PAT margin also increasing to 15.2% for the quarter, in line with our EBITDA performance. PAT has grown from INR 917 million in Q2FY25 to Rs 1,097 million in Q3FY25, a growth of 19.6% sequentially.” Result PDF
Conference Call with Indegene Ltd. Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.
Conference Call with Indegene Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Indegene announced Q1FY25 results: Achieved revenue of Rs 6,765 million in Q1FY25 with growth of 11.4% vs Q1FY24 Robust EBITDA growth of 14.5% in Q1FY25 vs Q1FY24 Became a zero-debt company Manish Gupta, Chairman and CEO, Indegene, said: “In Q1FY25, we achieved revenue growth of 11.4% and robust EBITDA growth of 14.5% vs Q1FY24. We continue to see momentum and growth with our largest client and a few of our Top 20 clients with increased activity and volume levels tracking the larger pipeline of impending new product launches" “Based on our conversations with our top clients, we anticipate similar momentum across the industry. Further, compared to last year, our pipeline is heathier and the quality of conversations with clients is much better, which gives us confidence about driving robust growth in the medium term.” Suhas Prabhu, CFO, Indegene, said: “Our Q1FY25 EBITDA margin of 19.6% and PAT margin of 13.0% is an improvement of 50 bps and 170 bps vs Q1FY24. Indegene is now a zero-debt company with repayment of loans, and we anticipate the financial leverage to drive stronger PAT growth going forward” “Also, we continue to strengthen our technology and automation initiatives, which we believe will have a positive impact on the margin in the future. Further, we anticipate that the EBITDA margin would have a similar trajectory as FY24 with a stronger H2 compared to H1.” Result PDF
Conference Call with Indegene Ltd. Management and Analysts on Q1FY25 Performance and Outlook. Listen to the full earnings transcript.
Consulting Services company Indegene announced FY24 results: FY24 Revenue up by 12.3% YoY, crosses Rs 2,500 crore FY24 EBITDA up 28.6%, and PAT up by 26.5% Yoy FY24 EBITDA% up by 286 bps, and PAT% up by 146 bps YoY Manish Gupta, Chairman and Chief Executive Officer - "We are pleased with our continued performance this quarter and the full year. Today in the marketplace we are known as a digital first commercialization partner to the global life sciences industry. We have 63 active clients and work with all the top 20 global pharmaceutical companies. Our revenues very closely mirrors the global life sciences industry's spends on operations. 69% of our revenues come from the top 20 Pharma companies. Global Life Sciences industry is more than USD 1.8 Tn Industry. We are excited about the opportunity in front of us." Suhas Prabhu, Chief Financial Officer - "Our financial results reflect our focus on operational excellence, cost optimization and value-driven service delivery. While revenue grew steadily, we delivered strong growth in margins, with a healthy cash conversion and a strong balance sheet, providing us with the flexibility to invest in growth opportunities. We remain committed to delivering value to our clients and shareholders through deep domain expertise, innovation and operational excellence." Result PDF